Search
Search Constraints
You searched for: Author/Creator Liello, Raimondo DiLimit your search
- Liello, Raimondo Di [remove] 1
- 616.994 1
- HNSCC -- Immunotherapy -- ICI -- R/M HNSCC -- ADCC -- Immunotherapy biomarkers 1
- Hematology -- Periodicals 1
- Oncology -- Periodicals 1
- PD-1 Programmed cell death protein 1 -- PD-L1 Programmed cell death Ligand-1 -- CTLA-4 Cytotoxic T-lymphocyte antigen 4 -- HNC Head and neck cancers -- NK Natural killer -- APC Antigen presenting cells -- EGFR Epidermal growth factor receptor -- STAT3 Signal transducer and activator of transcription 3 -- HPV Human papillomavirus -- Tregs Regulatory T-lymphocytes -- IL-10 Interleukin 10 -- TGF-β Transforming Growth Factor-beta -- TIM-3 Mucin domain-containing protein 3 -- LAG-3 Lymphocyte activation gene-3 -- IDO-1 Indoleamine- 2, 3-dioxygenase 1 -- ADCC Antibody-dependent cell-mediated cytotoxicity -- MAPK Mitogen-activated protein kinase -- PTEN Phosphoinositide phosphatase -- HNSCC Head and neck squamous cell carcinoma -- OSCC Oral cavity squamous cell carcinoma -- RT Radiation therapy -- ICIs Immune checkpoint inhibitors -- Ig Immunoglobulin -- ASCO American Society of Clinical Oncology -- pTR-2 Pathologic tumor response-2 -- pCR Pathologic complete response -- DFS Disease free survival -- CT Chemotherapy -- TE Tumor effect -- PD Progressive disease -- LA Locally advanced -- ESMO European Society for Medical Oncology -- ORR Overall response rate -- PR Partial response -- SD Stable disease -- CIAO Checkpoint Inhibitors Assessment in Oropharynx cancer -- TLR8 Toll-like receptor 8 -- PFS Progression free survival -- SoC Standard of care -- EFS Event-free survival -- OS Overall survival -- TMB Tumor mutational burden -- 5FU 5-fluorouracil -- OPC Oropharyngeal cancer -- HR Hazard ratio -- irAEs Immune-related adverse events -- MHNCS Multidisciplinary Head and Neck Cancers Symposium -- IMRT Intensity-modulated radiation therapy -- DLT Dose-limiting toxicity -- AEs Adverse events -- SAEs Serious adverse events -- DMC Data Monitoring Committee -- R/M Recurrent or metastatic -- QoL Quality of life -- FDA Food and Drug Administration -- ITT Intention-to-treat -- CPS Combined positive score -- AACR American Association for Cancer Research -- DOR Duration of response -- efti Eftilagimod alpha -- CR Complete response -- VEGFR Vascular endothelial growth factor receptor -- FGFR Fibroblast growth factor receptor -- PDGFR-α Platelet-derived growth factor receptor alfa -- RET Rearranged during transfection -- ECOG Eastern Cooperative Oncology Group -- PS Performance status -- ICOS Inducible T cells co-stimulator -- ICOSL Inducible T cells co-stimulator ligand -- BOR Best overall response -- TPS Tumor proportion score -- IHC Immunohistochemistry -- MSI Microsatellite instability -- MSI-H MSI-high -- GEP Gene-expression profiling 1